Merck & Co., Inc. (NYSE:MRK) PT Raised to $130.00 at Berenberg Bank

Merck & Co., Inc. (NYSE:MRK – Get Rating) had its price objective upped by Berenberg Bank from $125.00 to $130.00 in a report released on Friday, The Fly reports. Berenberg Bank’s price target indicates a potential upside of 20.72% from the company’s current price.

A number of other equities analysts have also commented on MRK. Cowen boosted their price objective on shares of Merck & Co., Inc. from $108.00 to $120.00 in a report on Tuesday, January 3rd. SVB Leerink upped their price target on shares of Merck & Co., Inc. from $120.00 to $122.00 and gave the stock an “outperform” rating in a research note on Friday, February 3rd. Barclays increased their target price on shares of Merck & Co., Inc. from $110.00 to $128.00 in a research note on Tuesday, December 20th. Citigroup boosted their price target on shares of Merck & Co., Inc. to $105.00 in a report on Tuesday, November 15th. Finally, Truist Financial upped their price objective on shares of Merck & Co., Inc. from $106.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, February 3rd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $119.60.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $107.69 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.47 and a debt-to-equity ratio of 0.62. The company has a market cap of $273.38 billion, a P/E ratio of 18.86, a PEG ratio of 1.97 and a beta of 0.34. Merck & Co., Inc. has a 52 week low of $77.31 and a 52 week high of $115.49. The company has a 50-day moving average price of $108.81 and a 200 day moving average price of $101.64.

Merck & Co., Inc. (NYSE:MRK – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.06. The business had revenue of $13.83 billion during the quarter, compared to analysts’ expectations of $13.66 billion. Merck & Co., Inc. had a net margin of 24.49% and a return on equity of 43.47%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the company posted $1.80 EPS. Research analysts predict that Merck & Co., Inc. will post 6.88 earnings per share for the current year.

Insider Buying and Selling

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $108.22, for a total value of $541,100.00. Following the transaction, the insider now directly owns 20,284 shares of the company’s stock, valued at approximately $2,195,134.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Joseph Romanelli sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $108.22, for a total value of $541,100.00. Following the sale, the insider now directly owns 20,284 shares of the company’s stock, valued at $2,195,134.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sanat Chattopadhyay sold 83,994 shares of the company’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $112.29, for a total value of $9,431,686.26. Following the completion of the sale, the insider now directly owns 29,500 shares in the company, valued at $3,312,555. The disclosure for this sale can be found here. Insiders sold 100,245 shares of company stock worth $11,168,256 in the last quarter. 0.29% of the stock is owned by insiders.

Institutional Trading of Merck & Co., Inc.

Hedge funds have recently bought and sold shares of the company. Retirement Financial Solutions LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Legend Financial Advisors Inc. acquired a new position in Merck & Co., Inc. in the 3rd quarter worth about $27,000. EdgeRock Capital LLC purchased a new stake in Merck & Co., Inc. during the 3rd quarter worth approximately $30,000. Mach 1 Financial Group LLC purchased a new stake in shares of Merck & Co., Inc. in the third quarter valued at approximately $30,000. Finally, New Millennium Group LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at $35,000. Hedge funds and other institutional investors own 72.89% of the company’s stock.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.